Coprococcus eutactus改善代谢相关性脂肪性肝病小鼠肝组织脂肪代谢实验研究*

doi:10.3969/j.issn.1672-5069.2025.06.004

实用肝脏病杂志 ›› 2025, Vol. 28 ›› Issue (6): 813-817.doi: 10.3969/j.issn.1672-5069.2025.06.004

Coprococcus eutactus改善代谢相关性脂肪性肝病小鼠肝组织脂肪代谢实验研究^*

杨思琪, 陈佳炜, 李少涵, 郭雪, 黄琛, 陈慧婷, 周永健

510180 广州市华南理工大学附属第二医院消化内科

收稿日期:2025-04-27 出版日期:2025-11-10 发布日期:2025-11-13
通讯作者: 周永健,E-mail:eyzhouyongjian@scut.edu.cn
作者简介:杨思琪,女,25岁,硕士研究生。E-mail:ysq990724@163.com;共同第一作者:陈佳炜,男,24岁,硕士研究生。E-mail:1640268475@qq.com
基金资助:
^*国家自然科学基金资助项目(编号:82170585);广东省科技厅科研计划项目(编号:2023A0505010007);广东省自然科学基金资助项目(编号:2021A1515011290);广东省卫济医学发展基金会消化病学专项科研基金资助项目(编号:K-202401210);广州市科技计划项目(编号:SL2023A04J00596/2023A03J0955);广州市重点医学学科建设项目(编号:2025-2027);广州市临床重点专科临床医学研究所建设项目(编号:2024-2026)

Improvement of liver steatosis of Coprococcus eutactus in mice with MCD-induced metabolic-associated fatty liver disease

Yang Siqi, Chen Jiawei, Li Shaohan, et al

Department of Gastroenterology and Hepatology, Second Affiliated Hospital School of Medicine, South China University of Technology, Guangzhou 510180, Guangdong Province, China

Received:2025-04-27 Online:2025-11-10 Published:2025-11-13

摘要/Abstract

摘要： 目的分析Coprococcus菌属对小鼠代谢相关脂肪性肝病(MAFLD)肝组织脂肪变的影响。方法构建db/db小鼠和MCD饮食诱导的MAFLD小鼠模型,并给予C.eutactus(10⁹ CFU/只/d)每日灌胃。实验结束后,收集血清和肝组织进行H&E染色、油红O染色和Masson,采用qPCR和Western blot法检测肝组织相关基因和蛋白表达。结果在db/db小鼠和MCD饮食诱导的MAFLD小鼠,C.eutactus干预使小鼠肝质量/体质量比值分别下降了12.9%和8.4%(P<0.05或P<0.01),血清ALT和AST水平较模型组分别下降了14.7%和37.2%(P<0.05或P<0.01);干预组肝组织细胞脂肪变性和炎性浸润明显改善;C. eutactus干预组肝组织与脂质代谢相关基因(FASN和Fabp5)mRNA水平较模型组分别下降了44.1%和52.7%(P<0.01); C. eutactus干预还显著抑制了肝组织炎症细胞因子(CCL3)和纤维化标志物(TGF-β1)蛋白表达。结论本研究结果提示C.eutactus能够通过抑制脂质合成、减轻炎症反应和延缓纤维化进程改善MAFLD病理学损伤,这些发现为未来针对MAFLD的个性化治疗提供了新的思路和理论依据。

Abstract: Objective This experiment aimed to observe improvement of liver steatosis of Coprococcus eutactus (C. eutactus) in mice with methionine-choline-deficent diet (MCD)-induced metabolic-associated fatty liver disease (MAFLD). Methods Two MAFLD mouse models, e.g., in db/db mice and in a MCD-induced mice, were established. The mice were randomly divided into control, model and C. eutactus –intervened (daily oral gavage of C. eutactus at 10⁹ CFU/mouse) groups. After finishing the experiment, serum samples were collected for biochemical analysis, and liver tissues were subjected to Hematoxylin & Eosin staining, oil red O staining and Masson staining. Quantitative real-time PCR and Western blotting were applied to investigate gene and protein expression. Results Pathological examination showed marked improvements in hepatocyte steatosis and inflammatory infiltration; qPCR analysis demonstrated that C. eutactus intervention significantly down-regulated mRNA levels of lipid metabolism-related genes (such as FASN and Fabp5) in mouse liver tissues compared to in the model group (decreased by 44.1% and 52.7%, respectively, P<0.01); furthermore, C. eutactus intervention greatly suppressed protein expression of inflammatory cytokines, such as CCL3, and fibrosis markers, as TGF-β1, in hepatic tissues compared to either in the control or in the model groups. Conclusion This study confirms that C. eutactus could ameliorate liver steatosis by inhibiting lipid synthesis, reducing inflammatory responses, and delaying fibrosis progression.

Key words: Metabolic-associated fatty liver disease, Coprococcus eutactus, Lipid metabolism, Liver fibrosis, Mice

杨思琪, 陈佳炜, 李少涵, 郭雪, 黄琛, 陈慧婷, 周永健. Coprococcus eutactus改善代谢相关性脂肪性肝病小鼠肝组织脂肪代谢实验研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 813-817.

Yang Siqi, Chen Jiawei, Li Shaohan, et al. Improvement of liver steatosis of Coprococcus eutactus in mice with MCD-induced metabolic-associated fatty liver disease[J]. Journal of Practical Hepatology, 2025, 28(6): 813-817.

参考文献

[1] Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol, 2020, 17(5): 279-297.
[2] Eslam M, Sanyal A J, George J, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020, 158(7): 1999-2014,e1.
[3] 柳雅立, 张晶. 儿童和青少年代谢相关脂肪性肝病研究进展. 实用肝脏病杂志, 2024, 27(4): 488-492.
[4] Friedman S L, Neuschwander-Tetri B A, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med, 2018, 24(7): 908-922.
[5] 王梦雨, 杨蕊旭, 范建高. 重视代谢相关脂肪性肝病的特征与预后临床研究. 实用肝脏病杂志, 2021, 24(3): 308-311.
[6] Sharpton S R, Schnabl B, Knight R, et al. Current concepts, opportunities, and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease. Cell Metab, 2021, 33(1): 21-32.
[7] Boursier J, Mueller O, Barret M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology, 2016, 63(3): 764-775.
[8] Alferink L J M, Radjabzadeh D, Erler N S, et al. Microbiomics, metabolomics, predicted metagenomics, and hepatic steatosis in a population-based study of 1,355 adults. Hepatology, 2021, 73(3): 968-982.
[9] Louis P, Flint H J. Formation of propionate and butyrate by the human colonic microbiota. Environ Microbiol, 2017, 19(1): 29-41.
[10] Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature, 2012, 490(7418): 55-60.
[11] Miao L, Targher G, Byrne C D, et al. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab, 2024, 35(8): 697-707.
[12] Canfora E E, Meex R C R, Venema K, et al. Gut microbial metabolites in obesity, NAFLD and T2DM. Nat Rev Endocrinol, 2019, 15(5): 261-273.
[13] Schwimmer J B, Johnson J S, Angeles J E, et al. Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease. Gastroenterology, 2019, 157(4): 1109-1122.
[14] Flessa C M, Nasiri-Ansari N, Kyrou I, et al. Genetic and diet-induced animal models for non-alcoholic fatty liver disease (NAFLD) research. Int J Mol Sci, 2022, 23(24): 15791.
[15] Suriano F, Vieira-Silva S, Falony G, et al. Novel insights into the genetically obese (ob/ob) and diabetic (db/db) mice: two sides of the same coin. Microbiome, 2021, 9: 147.
[16] Scorletti E, Carr R M. A new perspective on NAFLD: focusing on lipid droplets. J Hepatol, 2022, 76(4): 934-945.
[17] Sun D Q, Liu W Y, Wu S J, et al. Increased levels of low-density lipoprotein cholesterol within the normal range as a risk factor for nonalcoholic fatty liver disease. Oncotarget, 2016, 7(5): 5728-5737.
[18] Xiao Y, Yang Y, Xiong H, et al. The implications of FASN in immune cell biology and related diseases. Cell Death Dis, 2024, 15(1): 88.
[19] Sun J, Esplugues E, Bort A, et al. Fatty acid binding protein 5 suppression attenuates obesity-induced hepatocellular carcinoma by promoting ferroptosis and intratumoral immune rewiring. Nat Metab, 2024, 6(4): 741-763.
[20] Kumar V, Xin X, Ma J, et al. Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. Adv Drug Deliv Rev, 2021, 176: 113888.
[21] Ahmed H, Umar M I, Imran S, et al. TGF-β1 signaling can worsen NAFLD with liver fibrosis backdrop. Exp Mol Pathol, 2022, 124: 104733.
[22] Song Y, Wei J, Li R, et al. Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-β/SMAD signaling. Hepatology, 2023, 78(5): 1433.

Coprococcus eutactus改善代谢相关性脂肪性肝病小鼠肝组织脂肪代谢实验研究^*

Improvement of liver steatosis of Coprococcus eutactus in mice with MCD-induced metabolic-associated fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	李思思, 姜艳贞, 付兆媛. 中西医结合治疗肝纤维化研究进展与思考^*[J]. 实用肝脏病杂志, 2025, 28(6): 805-808.
[2]	陈杉杉, 司晓闯, 朱家宝, 谢淑慧, 吴静, 吴彬彬, 徐艳青, 梁燕楼, 王子弦, 孙亚楠. 多种无创诊断指标评估原发性胆汁性胆管炎患者肝硬化价值研究^*[J]. 实用肝脏病杂志, 2025, 28(6): 886-889.
[3]	王庆菁, 范建高, 沈峰, 张骞仁, 任天羿, 汪余勤. NAT10促进肝大部切除术小鼠肝再生实验研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 651-654.
[4]	汤洁, 姜正伟, 周冰清, 蒋蓓莉, 张睿. 超声剪切波弹性成像检查联合APRI和FIB-4诊断血清HBeAg阳性慢性乙型肝炎患者肝纤维化程度价值研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 663-666.
[5]	杨欢, 袁宏伟, 奇丽娜, 陈平. 代谢相关脂肪性肝病患者肝组织学表现研究^*[J]. 实用肝脏病杂志, 2025, 28(5): 711-714.
[6]	齐一菲, 于庆红, 白世锦, 刘琳, 范旭, 王萍, 丛敏, 刘天会. 二乙基二硫代氨基甲酸通过Insr/Akt通路改善代谢相关脂肪性肝炎体内和体外实验研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 501-504.
[7]	韩煜东, 张杰, 章文瑾, 何年安. 超声来源的脂肪分数诊断代谢相关脂肪性肝病应用研究[J]. 实用肝脏病杂志, 2025, 28(4): 553-556.
[8]	杨浩, 易波, 刘洪岩. T2DM合并代谢相关脂肪性肝病患者血清IFN-α和IFN-β水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(4): 557-560.
[9]	刘倩, 杨洁, 张静, 宫克, 郭瑞丹. 慢性乙型肝炎合并代谢相关脂肪性肝病患者外周血单个核细胞Galectin-3和Galectin-9水平及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(3): 338-341.
[10]	王钰, 刘洁, 樊健敏, 王成, 叶苗青. 超声声触诊弹性成像诊断慢性乙型肝炎患者肝纤维化价值研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 342-345.
[11]	卫涛涛, 刘天烨, 戴高中. 代谢相关脂肪性肝病患者回肠菌群特征研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 354-357.
[12]	董旭, 王超群, 陈怡, 朱彤, 葛玲玲, 徐爱静. 估算葡萄糖处置率评估无糖尿病人群代谢相关脂肪性肝病发生风险效能研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 362-365.
[13]	秦浩, 方春华, 何競, 张磊, 冉斌, 汪丽萍, 张振华. 六种无创评分诊断2型糖尿病合并代谢相关脂肪性肝病患者效能比较^*[J]. 实用肝脏病杂志, 2025, 28(3): 366-369.
[14]	王新田, 康晓波, 吴霞, 韦颖. 非酒精性脂肪性肝病患者血清OCN、β-CTX和血管紧张素水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(3): 378-381.
[15]	曾艾, 王聪, 李敏, 赵伊婷, 张琴, 何梅. 剪切波弹性成像联合APRI诊断2型糖尿病合并NAFLD患者肝纤维化程度价值研究^*[J]. 实用肝脏病杂志, 2025, 28(3): 382-385.